EMERALD: Subgroup analysis of patients with no prior chemotherapy in a phase 3 trial evaluating elacestrant versus investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC). ASCO 2022.

Poster